NasdaqGS:TXGLife Sciences
Assessing 10x Genomics (TXG) Valuation After Q1 2026 Results And Rising AI Trading Interest
Q1 earnings spark fresh interest in 10x Genomics
10x Genomics (TXG) has drawn renewed attention after reporting first quarter 2026 results that paired lower year-on-year revenue with a sharply smaller net loss, alongside increasingly discussed AI-driven and institutional trading activity.
See our latest analysis for 10x Genomics.
The share price is US$21.20 after a 1-month share price return that is down 18.71%, although the 90-day share price return is up 17.00%. The 1-year total shareholder...